Innova Captab Limited · NSE:INNOVACAP
Innova Captab — Q2 FY25 Earnings Presentation
35 slides from Innova Captab's earnings presentation, Nov 7, 2024
Slide 1: Intimation of Investor Presentation to Stock Exchanges
INNOVA CAPTAB LIMITED 1281/1, Hilltop Industrial Estate, Near EPIP, Phase-I, Jharmajri, Baddi, Dist. Solan (H.P.)-173205 India. Phone: +91-1795-650820 November 07, 2024 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Mum
Slide 2: Investor Presentation – November 2024
INVESTOR PRESENTATION – November 2024 1
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Innova Captab Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: Company Overview
Dg ac all = Br a5 > a &) Company Overview “(e) CAPTAB
Slide 5: One of the leading Integrated Pharmaceutical Player
One of the leading Integrated Pharmaceutical Player FY24 Highlights INR 1,094 crores INR 167 crores INR 94 crores 5 Third Largest Total Income EBITDA Profit after Tax New Greenfield Manufacturing Blocks Finished Tablet and Capsule 3 Baddi |1 Dehradun |1 Taloja Multipurpose Plant (4 manufacturing Man
Slide 6: Our Journey
Our Journey 2006 2010 2013 2015-17 2018-21 2022 2023 24 Foundation Establishment of International GMP Establishment of Further Expansion Strategic Expansion Acquisition of Sharon Cephalosporin plant Certification Marketing Arm • Innova Captab began • Further expanded • Commenced • Acquisition of its
Slide 7: Q2 & H1FY25 Performance Highlights
Q2 & H1FY25 Performance Highlights 6
Slide 8: MD’s Commentary
MD’s Commentary As we reflect on our Q2 and first half results for FY25, we are proud to report that our strategic initiatives are yielding tangible growth across all business areas, with a significant improvement in overall profitability. In Q2 FY25, we achieved YoY revenue growth of 12.5%, while H
Slide 9: Quarterly Performance Highlights
Quarterly Performance Highlights Revenue (INR Crores) EBITDA (INR Crores) PAT (INR Crores) +12.5% 15.5% 15.1% 16.3% 8.1% 10.0% 11.0% Margin 318.2 282.9 294.3 +18.6% 51.9 +52.8% 43.8 44.3 35.0 29.5 22.9 Q2FY24 Q1FY25 Q2FY25 Q2FY24 Q1FY25 Q2FY25 Q2FY24 Q1FY25 Q2FY25 Geography-Wise* (%) Business Areas
Slide 10: Half-Yearly Performance Highlights
Half-Yearly Performance Highlights Revenue (INR Crores) EBITDA (INR Crores) PAT (INR Crores) +18.7% 14.8% 15.7% 7.8% 10.5% Margin 612.5 +26.2% 516.2 +59.2% 96.2 76.2 64.5 40.5 H1FY24 H1FY25 H1FY24 H1FY25 H1FY24 H1FY25 Geography-Wise* (%) Business Areas (INR Crores) 612.5 Export 20% 24% 516.2 97.4 Sh
Slide 11: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit and Loss (INR crores) Q2 FY25 Q2 FY24 YoY Growth Q1 FY25 QoQ Growth H1 FY25 H1 FY24 YoY Growth Revenue from Operations 318.2 282.9 294.3 612.5 516.2 Other Income 2.2 3.3 2.1 4.3 4.5 Total Income 320.4 286.3 11.9% 296.4 8.1% 616.8 520.7 18.5% Cost of Materi
Slide 12: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (INR crores) Sept 2024 Mar 2024 Equity & Liabilities (INR crores) Sept 2024 Mar 2024 Non - Current Assets 849.5 741.1 Total Equity 895.3 830.9 Property, plant and equipment 295.7 291.6 Share Capital 57.2 57.2 Right of use assets 47.7 48.7 Other Equity 838.1 773.7 Ca
Slide 13: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (INR crores) H1 FY25 H1 FY24 Net Profit Before Tax 86.1 54.8 Adjustments for: Non -Cash Items / Other Investment or Financial Items 12.2 22.9 Operating profit before working capital changes 98.3 77.7 Changes in working capital (52.5) 11.0 Cash generated f
Slide 14: Jammu Facility: Final Stage Towards Commencement (1/2)
Jammu Facility: Final Stage Towards Commencement (1/2) Received Drug Manufacturing License 13
Slide 15: Jammu Facility: Final Stage Towards Commencement (2/2)
Jammu Facility: Final Stage Towards Commencement (2/2) 14
Slide 16: Key Strengths
Dg a al > GP BHSS) Key Strengths “(e) CAPTAB
Slide 17: Key Strengths
Key Strengths 01 02 03 Strong Capabilities to Diversified Product Customer Centric Deliver across the Portfolio Approach Globe 04 05 06 R&D Centric Experienced Consistent Financial Organization Promoters and Board Performance of Directors 16
Slide 18: 1. Diversified Product Portfolio
1. Diversified Product Portfolio H1FY25 Revenue mix CDMO Offer multiple dosage forms Including- 1. 2,900+ CDMO Products | 190+ Oral solids | Oral Liquids | Dry syrups | Dry powder injectables | Ointments 54% Customers • Our branded generics business focuses on distributing and marketing Domestic Bra
Slide 19: 2. Customer Centric Approach
2. Customer Centric Approach Revenue from Customers with Number of CDMO Customers Revenue from CDMO (INR crores) >5 years relationship1 (INR crores) FY21 119 371 338 FY22 174 687 603 FY23 182 680 572 FY24 193 622 522 Cultivated Strong Relationships within the Indian Pharmaceutical Industry 190+ 14 o
Slide 20: 3. State of the Art Manufacturing Capabilities
3. State of the Art Manufacturing Capabilities Installed Capacity (FY24) Jammu (Greenfield Project) [4 Blocks] Location Block Products Capacity Utilized (%) Upcoming R&D Baddi, Himachal Pradesh (2 Units) [3 Blocks] R&D Facility in Baddi, Himachal Pradesh Tablets 8,192 mn 44% Facility in Panchkula, C
Slide 21: 4. R&D Centric Organisation
4. R&D Centric Organisation Robust Research and Development Dedicated R&D facility and pilot equipment located in Baddi, Himachal Pradesh, recognized by the DSIR for its in-house R&D 01 work. State-of-the-art facility equipped with a comprehensive suite of necessary tools for developing solid oral a
Slide 22: 5. Experienced Promoters and Board of Directors
5. Experienced Promoters and Board of Directors Manoj Kumar Lohariwala Vinay Kumar Lohariwala Jayant Vasudeo Rao Archit Aggarwal Chairman & Whole-time Director Managing Director Whole-time Director Non-Executive Director ▪ Bachelor’s in Commerce from Mohta ▪ Bachelor’s in Engineering (Mechanical) ▪
Slide 23: 6. Consistent Financial Performance
6. Consistent Financial Performance Revenue (INR crores) EBITDA (INR crores) PAT (INR crores) 13.6% 12.4% 13.3% 15.4% 8.4% 8.0% 7.3% 8.7% Margin +38% 1,081 926 +44% 167 801 123 +39% 94 99 68 411 64 56 35 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 ROE/ROCE (%)1 Fixed Asset Turnover (
Slide 24: Growth Strategies
Dg ac all = Br a5 > a &) Growth Strategies “(e) CAPTAB
Slide 25: Multiple Levers for Growth
Multiple Levers for Growth 01. Expansion of Manufacturing Capabilities 02. Expansion of Wallet Share 03. Continued Focus on R&D o To expand business with existing o To expand research activities for both o CDMO is an essential segment of the customers while also cultivating new CDMO and Internationa
Slide 26: Long Runway of Growth
Long Runway of Growth Baddi Plant Dehradun | Taloja Plant Greenfield project at Jammu 20%-30% 20% - 25% 15% - 20% INR 190 crores* INR 865 crores 70%-75% 40%-50% 50% -60% 70% - 75% Capacity 45% 70% - 75% 45% -- 50% 50% 70% - 75% Utilization FY24 Un-utilized Optimum FY24 Un-utilized Optimum FY25 - To
Slide 27: Historical Financial Performance
Historical Financial Performance 26
Slide 28: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit and Loss (INR crores) FY24 FY23 FY22 FY21 Revenue from Operations 1,081.3 926.4 800.5 410.7 Other Income 12.5 9.2 2.9 1.4 Total Revenue 1,093.8 935.6 803.4 412.0 Cost of Materials Consumed 728.3 691.6 617.9 310.7 Employee Cost 90.7 54.8 40.5 22.3 Other Exp
Slide 29: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (INR crores) FY24 FY23 FY22 FY21 Equity & Liabilities (INR crores) FY24 FY23 FY22 FY21 Non - Current Assets 741.1 261.9 196.4 99.1 Total Equity 830.9 276.5 208.6 144.8 Property, plant and equipment 291.6 150.1 156.6 76.4 Share Capital 57.2 48.0 12.0 12.0 Right of us
Slide 30: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (INR crores) FY24 FY23 FY22 FY21 Net Profit Before Tax 129.5 91.8 85.7 46.3 Adjustments for: Non -Cash Items / Other Investment or Financial Items -37.2 -25.9 -15.3 -9.6 Operating profit before working capital changes 166.7 117.7 101.0 55.9 Changes in wor
Slide 31: Industry Overview
Dg ac all = Br a5 > a &) Industry Overview “(e) CAPTAB
Slide 32: Indian Formulations Market – Poised for Healthy Growth
Indian Formulations Market – Poised for Healthy Growth Domestic Formulations Market to Grow at Double Digit Rate (INR Tn) Indian Formulations Exports Trend (USD Bn) 25.0 -27.0 19.1 13.0-15.0 12.9 10.6 1.04 1.47 2.6 – 2.7 6.9 11.0-13.0 8.5 CAGR: 7.5% CAGR: 10-12% 6.0 FY2016 FY2021 FY2026E Semi-regula
Slide 33: Indian CDMO Market – Overview
Indian CDMO Market – Overview Outsourcing of production activities to third-party vendors Big pharmaceutical companies prefer to outsource R&D as well as manufacturing activities in order to move to an asset light model. Most contract development and manufacturing organizations (CDMOs) cater to the
Slide 34: Indian CDMO Market Expected to sustain its Strong Growth Trajectory
Indian CDMO Market Expected to sustain its Strong Growth Trajectory Review and outlook on Indian CDMO market (INR Bn) Key Growth Drivers FY23 – FY28: ~12-14% CAGR Rising trend of outsourcing among the pharmaceutical industry players 2,400 – 2,500 Rising demand for generics FY18 – FY23: ~14% CAGR 1,3
Slide 35: Thank You!
Thank You! Innova Captab Limited : Investor Relations Advisor : http://www.sgapl.net/images/sgapl_logo.jpg Strategic Growth Advisors Pvt. Ltd. Innova Captab Ltd. CIN - U74140MH2010PTC204285 CIN – L24246MH2005PLC150371 Ms. Shaily Patwa / Mr. Shrikant Sangani Mr. Lokesh Bhasin / Mr. Ayush Kumar Garg E